Publication list - The Faculty of Health Sciences: Linköping ...

642 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
642
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Publication list - The Faculty of Health Sciences: Linköping ...

  1. 1. Sven Almer – List of publications<br />1. Published papers; original research communications<br />Taipalensuu J, Slånemyr E, Christiansson M, Andreasson H, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Colombel JF for the EPIMAD group, Lémann M for the GETAID group, Hugot JP, Almer S. Genetic association between Crohn’s disease and a marker located in the region of CLDN2 – MORC4 implicates the intestinal barrier as a primary risk factor. Submitted. <br />Rajani R, Björnsson E, Bergquist A, Danielsson Å, Gustavsson A, Grip O, Melin T, Sangfelt P, Wallerstedt S, Almer S. Incidence, prevalence and prognosis in portal vein thrombosis. A multicenter study of 173 patients. Submitted.<br />Haglund S, Vikingsson S, Taipalensuu J, Hindorf U, Grännö C, Danelius M, Coulthard S, Peterson C, Almer S. The role of inosine-5´-monophosphate dehydrogenase for a “skewed” thiopurine metabolite profile. Submitted.<br />Boström EA, Ekstedt M, Kechagias S, Sjöwall C, Bokarewa MI, Almer S. Resistin is elevated in autoimmune diseases of the gastrointestinal tract reflecting ANA positivity. Submitted.<br />Almer S. Novel strategies in the thiopurine treatment of inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2010; accepted.<br />Vikingsson S, Carlsson B, Almer S, Peterson C. How should thiopurine treatment be monitored? – Methodological aspects. Nucleosides Nucleotides Nucleic Acids 2010; accepted.<br />Werner M, Wallerstedt S, Lindgren S, Almer S, Björnsson E, Bergqvist A, Prytz H, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Ohlsson R, Danielsson Å. Characteristics and outcome in Swedish patients with autoimmune hepatitis with regard to the initial therapeutic response. Scand J Gastroenterol 2010;Epub Jan 18.<br />Hindorf U, Jaheed K, Bergqvist A, Verbaan H, Prytz H, Wallerstedt S, Werner M, Olsson R, Björnsson E, Peterson C, Almer SHC. Characterization and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52:106-11.<br />Elmberg M, Hultcrantz R, Ebrahim F, Olsson S, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H, Ekbom A, Askling J. Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology 2009;137:1301-9.<br />Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H. Factors predicting the outcome of disease activity assessment in Crohn’s disease. Inflam Bowel Disease 2009;15:1859-66. <br />Mesterton J, Jönsson L, Almer SHC, Befrits R, Friis-Liby IL, Lindgren S. Resource use and societal costs for Crohn’s disease in Sweden. Inflam Bowel Disease 2009;15:1882-90.<br />Myrelid P, Olaison G, Sjödahl R, Nyström PO, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease. Dis Colon Rectum 2009;52:1387-94.<br />Vikingsson S, Carlsson B, Almer SHC, Peterson C. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease - What is actually measured? Therapeutic Drug Monit 2009;31:345-50.<br />Lindgren S, Glaumann H, Almer S, Bergqvist A, Björnsson E, Broomé U, Danielsson Å, Lebrun B, Prytz H, Olsson R. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Int Med 2009;20:398-402.<br />Olsson R, Glaumann H, Almer S, Broomé U, Lebrun B, Bergquist A, Björnsson E, Prytz H, Danielsson Å, Lindgren S. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Int Med 2009;20:190-6.<br />Thiébaut R, Kotti S, Merlin F, Colombel J.F. for the EPIMAD group, Lemann M. for the GETAID group, Almer S, Tysk C, O’Morain M, Gassull M, Binder V, Finkel Y, Pascoe L, Hugot J.P. TNFSF15 polymorphisms are associated with susceptibility to Crohn’s Disease in a new European cohort. Am J Gastroenterol 2009;104:384-91.<br />Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SHC. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharm Ther 2009; 2009;29:654-61.<br />Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Björnsson E, Bergqvist A, Sandberg- Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson Å. Hepatic and extrahepatic malignancies in Autoimmune Hepatitis. A study by the ten University Hospitals in Sweden. J Hepatol 2009;50:388-93. <br />Almer S, Hjortswang H, Hindorf U. 6-Thioguanine therapy in Crohn’s disease – a Swedish experience. Dig Liver Diseases 2009;41:194-200.<br />Rajani R, Melin T, Björnsson E, Broomé U, Sangfelt P, Danielsson Å, Gustavsson A, Grip O, Svensson H, Lööf L, Wallerstedt S, Almer SH. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival – an 18-year experience. Liver Int 2009;29:253-9.<br />Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfeldt P, Weiland O, Danielsson Å. Epidemiology and the initial presentation of Autoimmune hepatitis in Sweden. Scand J Gastroenterol 2008;43:1232-40.<br />Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson Å, Lindgren S, Prytz H, Hultcrantz R, Lööf L, Sandberg-Gertzén H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis (PSC) and ulcerative colitis in first-degree relatives of patients with PSC. Clin Gastroenterol Hepatol 2008;6:939-43.<br />Noren B, Lundberg P, Dahlqvist O, Almer S, Kechagias S, Ekstedt M, Franzén L, Wirell S, Smedby Ö. Separation of advanced from mild fibrosis in diffuse liver disease 31P magnetic resonance spectroscopy. Eur J Radiol 2008;66:313-20.<br />Teml A, Schwab M, Hommes D, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr 2007;119:519-26.<br />Haglund S, Taipalensuu J, Peterson C, Almer S. Inosine-5-monophosphate dehydrogenase activity in patients with inflammatory bowel disease treated with thiopurines – relation to TPMT-activity and metabolite concentrations. Br J Clin Pharmacol 2008;65:69-77.<br />Lindqvist M, Skoglund K, Karlgren A, Söderkvist P, Peterson C, Almer S. Explaining TPMT genotype/phenotype discrepancy by haplotypic characterization of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenetics and Genomics 2007;17:891-5.<br />Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson Å, Sandberg-Gertzén H, Lööf L, Prytz H, Björnsson E. Acute liver failure in Sweden: etiology and outcome. J Int Med 2007;262:393-401.<br />Werner M, Björnsson E, Prytz H, Lindgren S, Almer S, Broomé U, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfeldt P, Nilsson J, Danielsson Å. Autoimmune hepatitis among fertile women: Strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42:986-91.<br />Almer S, Granerus G, Ström M, Olaison G, Bonnet J, Lémann M, Smedh K, Franzén L, Bertheau P, Cattan P, Rain JD, Modigliani R. Leukocyte scintigraphy compared to intraoperative small bowel enteroscopy and laparotomy findings in Crohn's disease. Inflamm Bowel Dis 2007;13:164-74.<br />Wallerstedt S, Olsson R, Simrén M,. Broomé U, Wahlin S, Lööf L, Hultcrantz R, Sjöberg K, Sandberg-Gertzen H, Prytz H, Almer S. Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis. Eur J Int Med 2007;18:44-7.<br />Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Lajord Munk O and the Swedish Internal Medicine Liver Club. Dynamic FDG PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006;44:1572-80.<br />Lindqvist M, Hindorf U, Almer S, Söderkvist P, Ström M, Hjortswang H, Peterson C. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides, Nucleotides and Nucleic Acids 2006;25:1033-7.<br />Myrelid P, Svärm S, Andersson P, Almer S, Bodemar G, Olaison G. Azathioprine as postoperative prophylaxis reduces symptoms in aggressive Crohn’s disease. Scand J Gastroenterol 2006;41:1190-5.<br />Hjortswang H, Järnerot G, Curman B, Sandberg-Gertzén H, Tysk C, Blomberg B, Almer S, Ström M. The short health scale: a valid measure of subjective health status in ulcerative colitis. Scand J Gastroenterol 2006;41:1196-1203.<br />Nyblom H, Björnsson E, Simren M, Aldenborg F, Almer S, Olsson R. The AST/ALT-ratio as an indicator of cirrrhosis in patients with PBC. Liver Int 2006;26:840-5.<br />Hindorf, U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of azathioprine-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:331-42.<br />Stjernman H, Grännö G, Bodemar G, Järnerot G, Ockander L, Tysk C, Blomberg B, Almer S, Ström M, Hjortswang H. Evaluation of the Inflammatory Bowel Disease Questionnaire in Swedish patients with Crohn’s disease. Scand J Gastroenterol 2006;41:934-43.<br />Hindorf, U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, Pousette A, Almer S. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55:1423-31.<br />de Boer NKH, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkuhn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Seiderer J, Vogelsang H, Mulder CJJ. 6-thioguanine (6-TG) treatment in inflammatory bowel disease: a critical appraisal by an European 6-TG working party. Digestion 2006;73:25-31.<br />Nayeri F, Aili D, Nayeri T, Xu J, Almer S, Lundström I, Åkerlind B, Liedberg B. Hepatocyte growth factor (HGF) in faecal samples: rapid detection by surface plasmon resonance. BMC Gastroenterol. 2005 Apr 12;5(1):13.<br />Noren B, Lundberg P, Ressner M, Wirell S, Almer S, Smedby Ö. Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease. Eur Radiol 2005;15:148-57.<br />Lindqvist M, Haglund S, Almer S, Peterson C, Taipalensu J, Hertervig E, Lyrenäs E, Söderkvist P. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004;14:261-5.<br />Nayeri F, Nilsson I, Brudin L, Almer S. Stability of faecal hepatocyte growth factor determination. Scand J Clin Lab Invest 2004;64:589-98.<br />Haglund S, Lindqvist M, Almer S, Peterson C, Taipalensuu J. Pyrosequencing of Thiopurine S-methyltransferase alleles in a Swedish background population and in patients with inflammatory bowel disease. Clinical Chemistry 2004;50:288-95. <br />Hindorf U, Peterson C, Almer S. Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population. Ther Drug Monit 2004;26;673-8.<br />Bodemar G, Kechagias S, Almer S, Danielsson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004;39:454-458. <br />Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson KS, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H, Askling J. Cancer risk in patients with hereditary hemocromatosis and in their first-degree realtives. Gastroenterology 2003;125:1733-41.<br />Hjortswang H, Järnerot G, Curman B, Sandberg-Gertzén H, Tysk C, Blomberg B, Almer S, Ström M. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:1011-20.<br />Lindqvist M, Almer S, Peterson C, Söderkvist P. Real time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression. Eur J Clin Pharm 2003;59:207-11.<br />Hugot JP, Cézard JP, Colombel JF, Almer S, Tysk C, Montague S, Gassull M, Christensen S, Finkel Y, Gower-Rousseau C, Modigliani R, Zouali H, Lesage S, Chamaillard M, Macry J, Thomas G,. Victor JM, Belaiche J. Clustering of Crohn’s disease within affected sibships. Eur J Hum Gen 2003;11:179-84.<br />Nayeri F, Almer S, Brudin L, Nilsson I, Åkerlind B, Forsberg P. High hepatocyte growth factor levels in faeces during acute infectious gastroenteritis. Scand J Inf Dis 2003;35:858-62.<br />Zouali H, Lesage S, Merlin F , Cézard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull M, Christensen S, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Chamaillard M, Thomas G, Hugot JP. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003;52:71-4.<br />Sjöwall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002;19:155-60.<br />Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit. 2002;24:351-8.<br />Broomé U, Glaumann H, Lindström E, Lööf L, Almer S, Prytz H, Sandberg-Gertzén H, Lindgren S, Fork FT, Järnerot G, Olsson R. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586-9.<br />Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson Å, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.<br />Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O'Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot AS, Thomas G, Hugot JP. CARD15/NOD2 Mutational Analysis and Genotype-Phenotype Correlation in 612 Patients with Inflammatory Bowel Disease. Am J Hum Genet. 2002;70:845-57.<br />Hugot JP Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J and GETAID, Almer S, Tysk C, Montague S, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of Nod-2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.<br />Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, Sperber A, Toner B, Drossman DA. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:1822-30.<br />Hjortswang H, Järnerot G, Curman B, Sandberg-Gertzén H, Tysk C, Blomberg B, Almer S, Ström M. Validation of the inflammatory bowel disease questionnaire (IBDQ) in Swedish patients with ulcerative colitis. Scand J Gastroenterol 2001:36:77-85.<br />Zouali H, Chamaillard M, Lesage S, Cézard JP, Colombel JF, Belaiche J and GETAID, Almer S, Tysk C, Montague S, Gassull M, Christensen S, Finkel Y, Gower-Rousseau C, Modigliani R, Macry J, Selinger-Leneman H, Thomas G, Hugot JP. Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel disease. Eur J Hum Gen 2001;9:731-42.<br />Lesage S, Zouali H, Colombel JF and EPIMAD, Belaiche J and GETAID, Cézard JP and EPGWGIBD, Tysk C, Almer S, Gassull M, Binder V, Chamaillard M, Le Gall I, Thomas G, Hugot JP. Genetic analyses of chromosome 12 loci in Crohn’s disease. Gut 2000;47:787-91.<br />Hjortswang H, Almer S, Ström M. The network - a strategy to decribe the relation between quality of life and disease activity. The case of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:1099-1104.<br />Hjortswang H, Ström M, Almer S. Health related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol 1998;93:2203-11.<br />Andersson P, Olaison G, Bodemar G, Almer S, Arvidsson M, Dabrosin-Söderholm J, Nyström PO, Smedh K, Ström M, Sjödahl R. Low symptomatic load in Crohn’s disease with surgery and medicine as complementary treatments. Scand J Gastroenterol 1998;33:423-9.<br />Hjortswang H, Ström M, Almeida R, Almer S. Evaluation of the RFIPC, a disease specific health related quality of life questionnaire, in Swedish patients with ulcerative colitis. Scand J Gastroenterol 1997;32:1235-40.<br />Almeida R, Hjortswang H, Ström M, Almer S, Persson J. Technology assessment using the association between outcome measures and patterns of illness severity. Med Biol Eng Compact 1997;35:386-90.<br />Almer S, Franzén F, Granerus G, Ström M. Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leucocytes than with antigranulocyte antibodies. Eur J Nucl Med 1996;23:247-55.<br />Almer S, Kald B, Franzén L, Ström M, Tagesson C. Concentrations of platelet activating factor in rectal mucosa in patients with ulcerative colitis. Eur J Surg 1996;162;391-6.<br />Almer S, Ljunghusen O, Lundahl J. Labelling of leucocytes with technetium-99m exametazime causes in vitro upregulation of granulocyt CD11b without correlation to tissue uptake in vivo. Eur J Nucl Med 1996;23:669-74.<br />Almer S, Bodemar G, Franzén F, Lindström E, Nyström PO, Ström M. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996;347:1731-5.<br />Almer S, Bodemar G, Franzén L, Lindström E, Norén B, Ström M. Plain X-ray films and air enema films reflect severe mucosal inflammation in acute ulcerative colitis. Digestion 1995;56:528-33.<br />Almer S, Bodemar G, Lindström E, Peters AM, Ström M. Air enema radiology compared with leukocyte scintigraphy for imaging inflammation in active ulcerative colitis. Eur J Gastro Hepatol 1995;7:59-64.<br />Almer S, Ljunghusen O. Upregulation of granulocyte CD 11b (CR 3) after labelling with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med 1995;22:1039-41.<br />Almer S, Peters AM, Ekberg S, Franzén L, Granerus G, Ström M. Is computer-aided interpretation of 99Tcm-HMPAO leukocyte scans better than the naked eye? Nucl Med Comm 1995;16:290-8.<br />Aisenberg J, Wagreich J, Shim J, Almer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, Mayer L, Sachar D. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Dig Dis Sci 1995;40:1866-72.<br />Almer S, Franzén L, Olaison G, Smedh K, Ström M. Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis. Gut 1993;34:509-13.<br />Peen E, Almer S, Bodemar G, Rydén BO, Sjölin C, Tejle K, Skogh T. Anti-lacto-ferrin antibodies and other types of ANCA in ulcerative colits, primary sclerosing cholangitis, and Crohn’s disease. Gut 1993;34:56-62.<br />Melander M, Almer S, Ström M. Clonidine in ulcerative colitis and proctitis. J Int Med 1993;233:93-4.<br />Almer S, Andersson T, Ström M. Pharmacokinetics of tranexamic acid in patients with ulcerative colitis and in healthy volunteers after the single instillation of 2 g rectally. J Clin Pharmacol 1992;32:49-54.<br />Almer S, Franzén L, Peters AM, Tjädermo M, Ekberg S, Granerus G, Ström M. Do technetium-99m hexamethylpropylene amine oxime labelled leukocytes truly reflect the mucosal inflammation in patients with ulcerative colitis? Scand J Gastroenterol 1992;27:1031-8.<br />Almer S, Ekberg S, Ström M. Retrograde distribution of a new 5-aminosalicylic acid enema in patients with ulcerative colitis. Gastroenterol Clin Biol 1992;16:564-8.<br />Almer S, Franzén L, Olaison G, Smedh K, Ström M. Phospholipase A2 activity of colonic mucosa in patients with ulcerative colitis. Digestion 1991;50: 135-41.<br />Almer S, Norlander B, Ström M, Osterwald H. Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. Scand J Gastroenterol 1991;26:327-35.<br />2. Papers under editorial considerations in international journals<br />Boström EA, Ekstedt M, Kechagias S, Sjöwall C, Bokarewa MI, Almer S. Resistin is elevated in autoimmune diseases of the gastrointestinal tract reflecting ANA positivity.<br />Haglund S, Vikingsson S, Taipalensuu J, Hindorf U, Grännö C, Danelius M, Coulthard S, Peterson C, Almer S. The role of inosine-5´-monophosphate dehydrogenase for a “skewed” thiopurine metabolite profile.<br />Rajani R, Björnsson E, Bergquist A, Danielsson Å, Gustavsson A, Grip O, Melin T, Sangfelt P, Wallerstedt S, Almer SHC. Incidence, prevalence and prognosis of portal vein thrombosis. A multi-center study of 173 patients.<br />Taipalensuu J, Slånemyr E, Christiansson M, Andreasson H, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Colombel JFfor the EPIMAD group, Lémann M for the GETAID group, Hugot JP, Almer SHC. Genetic association between Crohn’s disease and a marker located in the region of CLDN2 – MORC4 implicates the intestinal barrier as a primary risk factor. <br />van Asseldonk DP, Sanderson J, de Boer NKH, Sparrow MP, Lémann M, Ansari AR, Almer S, Florin T, Gearry R, Mulder CJ, Mantzaris G, van Bodegraven AA on behalf of the Thiopurine Task Force Interest group. Difficulties with thiopurine therapy in inflammatory bowel disease -– proceedings of the first Thiopurine Task Force meeting. <br />3. Invited Reviews<br />Lindqvist M, Hindorf U, Almer S, Peterson C. Thiopurines in inflammatory bowel disease – the role of pharmacogenetics and therapeutic drug monitoring. Current Pharmacogenomics 2006;4:285-300.<br />4. Manuscripts in preparation<br />Vujic A, Blomgran Julinder R, Almer S. Differential effects of thiopurines on neutrophil function.<br />Nordblom H, Ersmarker C, Hägg S, Weisselberg T, Almer S. Prevalence of adverse drug reactions in an unselected cohort of 233 inflammatory bowel disease patients.<br />Rustscheff S, Hultén S, Almer S. Eosinophilic enteritis. Asthma of the gut? Long-term follow-up of two patients with eosinophilic enteritis and concomitant asthma bronchiale successfully treated with montelukast.<br />Weisselberg T, Theorin N, Lotfi K, Almer SHC. Need for gastrointestinal investigations in patients undergoing haematopoietic stem cell transplantation.<br />Vikingsson S, Carlsson B, Almer S, Peterson C. Identification of methylthioinosine di- and triphosphates during oral thiopurine treatment of IBD patients.<br />Aleman S, Endalib S, Elmberg M, Stål P, Olsson R, Lööf L, Lindgren S, Sandberg-Gertzén H, Almer S, Olsson KS, Danielsson Å, Wallerstedt S, Hagen K, Hultcrantz R. The impact of detection routes on long-term survival of Swedish patients with hereditary hemocromatosis.<br />Schoultz I, Carlsson A, Gullberg E, Almer S, Ström M, Lerm M, McKay DM, Rhodes JM, Söderholm JD. Infliximab reduces bacterial uptake in mucosal biopsies of Crohn’s colitis via microtubule-dependent pathway.<br />Stjernman H, Tysk C, Almer S, Ström M, Hjortswang H. Worries and concerns among patients with Crohn’s disease.<br />Rajani R, Bergquist A, Melin T, Friis-Liby I, Kapraali M, Werner M, Sangfelt P, Wallerstedt S, Lindahl T, Almer S. Increased levels of factor VIII activity in plasma of patietnes with portal venous thromboses and Budd-Chiari syndrome.<br />Rajani R, Haglund S, Bergquist A, Melin T, Friis-Liby I, Verbaan H, Kapraali M, Werner M, Sangfelt P, Wallerstedt S, Almer S. High frequency of JAK2-mutation in Swedish patients with Budd-Chiari syndrome and portal venous thromboses.<br />5. Scientific papers published in national journals or on the Internet<br />Almer S, Haglund S, Hindorf U. Nya aspekter på tiopurinbehandling av inflammatorisk tarmsjukdom. Gastrokuiren 2010;15: in press.<br />Rajani R, Almer S. Levernära venösa tromboser. Vaskulär Medicin 2010; in press.<br />Almer S, Befrits R, Eriksson AS, Halfvarson J, Hindorf U, Löfberg R. Modern läkemedelsterapi vid Crohn - nationella riktlinjer. Läkartidningen 2009;106:2988-93.<br />Tysk C, Almer S, Andersson MV, Befrits R, Hertervig E, Kilander A, Lindgren S, Suhr O. Handläggning av svårt skov av ulcerös kolit. Läkartidningen 2009;106:2994-8.<br />Tysk C, Almer S, Andersson M, Befrits R, Hertervig E, Kilander A, Lindgren S, Suhr O. Nationella riktlinjer för handläggning av akut svårt skov av ulcerös kolit. http://www.svenskgastroenterologi.se/Nationella_riktlinje_ulceros_%20kolit_2008.doc<br />Almer S, Hindorf U. Inflammatorisk tarmsjukdom (IBD) och biologiska läkemedel. 2008.http://www.internetmedicin.se/dyn_main.asp?page=2184.<br />Björnsson E, Wei G, Bergquist A, Broomé U, Wallerstedt S, Almer S, Sangfelt P, Danielsson Å, Sandberg-Gertzén H, Lööf L, Prytz H, Lindgren S. Akut leversvikt – viktigt med snabb multidisciplinär handläggning. Läkartidningen 2007;104:210-3.<br />Rajani R, Almer S. Budd-Chiaris syndrom. 2007. http://www.internetmedicin.se/dyn_main.asp?page=2124.<br />Rajani R, Almer S. Portavenstrombos. 2007. http://www.internetmedicin.se/dyn_main.asp?page=2222.<br />Almer S. Genetiskt genombrott 2: NOD2-genen och Crohns sjukdom. Läkartidningen 2001;98:3809.<br />Almer S. Genetiskt genombrott vid inflammatorisk tarmsjukdom. Läkartidningen 2001;98:2795.<br />Almer S, Tysk C, Löfberg R. Nytt om ärftligheten vid inflammatorisk tarmsjukdom. Specifika gener kartläggs i EU-projekt. Läkartidningen 1998;95:3666-8.<br />Almer S, Smedh K. Leukocytskintigrafi, tunntarmsendoskopi, luftkolonröntgen. Nya metoder vid kolit och Crohns sjukdom. Läkartidningen 1998;95:860-2, 865-6.<br />Öhman L, Frydén A, Almer S, Tropp H. Clostridium difficile-enterit komplicerad med symfysit. God effekt av fekala streptokocker. Läkartidningen 1993;90:1954-6.<br />Almer S, Carlsson P, Fåhraeus L, Jansson I, Myrnerts R. Datakvalitet i ett patientregister. Läkartidningen 1990;87:1335-8<br />Almer S, Bodemar G, Rydén BO, Elfström J, Franzén L, Ihse I, Resjö M. P-piller och blodsjukdomar vanligaste orsakerna till Budd-Chiaris syndrom. Läkartidningen 1989;86:4002-4, 4007-8.<br />Almer S, Westerberg CE. Potentiella risker kräver ny uppmärksamhet. Hjärninfarkt hos 18-åring efter karateslag. Läkartidningen 1985; 82:2886-8.<br />Almer S, Westerberg CE. Infarctus cérébral à la suite d'un combat de karaté. La Presse Médicale 1985;14:2299.<br />Almer S, Jonasson B. Telefonrådgivning i primärvård. Läkartidningen 1984; 81:2155-77.<br />Almer S, Herrlin-Dallner B, Briem H, Gustavsson-Moringlane I. Oklar symtombild försvårar diagnostiken av hjärnabscess. Läkartidningen 1982;79:2033-4.<br />6. Correspondence<br />Rajani R, Almer SHC. Letter to the Editor regarding review of recent advances in Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome by Professor D-C Valla (Gut 2008;57:1469-78). Gut 2009;58:889.<br />Olaison G, Almer S, Andersson P. Perianal Crohn's disease Br J Surg. 2004 Oct;91(10):1381.<br />Rampton DS, Neurath MF, Almer S, D’Haens G, Petritsch W, Stange EF. Mycophenolate mofetil in Crohn’s disease. Lancet 2000;354:163-4<br />7. Meeting reports<br />Fransson M, Fritzson P, Lindqvist M, Hindorf U, Almer S, Peterson C. A preliminary study of modeling and simulation in individualized drug dosage – azathioprine on inflammatory bowel disease. The 47th Conference on Simulation and Modeling of the Scandinavian Simulation Society 2006;216-220. Helsinki: Kopio Niini Oy.<br />8. Text books<br />Almer S, Rajani R. Cirkulatoriska leversjukdomar. Book chapter. In: Hultcrantz R (ed): gastroenterologi och Hepatologi. Liber förlag, Stockholm 2010. <br />Almer S. Infektions- och inflammationsscintigrafi. Book chapter Almer S, Hietala SO, Riklund Åhlström K. ‘Övrig diagnostik’ in: Hietala SO, ed. Nuklearmedicin, Lund; Studentlitteratur 1998;129-46.<br />

×